Core Viewpoint - BillionToOne, Inc. has launched a roadshow for its proposed initial public offering (IPO) of 3,846,000 shares of Class A common stock, with an expected price range of $49.00 to $55.00 per share [1]. Company Overview - BillionToOne is a molecular diagnostics company based in Menlo Park, California, focused on creating powerful and accurate tests that are accessible to all [4]. - The company utilizes a patented technology called Quantitative Counting Templates™ (QCT™), which is the only multiplex technology capable of accurately counting DNA molecules at the single-molecule level [4]. IPO Details - The proposed IPO includes a 30-day option for underwriters to purchase an additional 576,900 shares at the initial offering price, excluding underwriting discounts and commissions [1]. - The company has applied to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol "BLLN" [1]. - J.P. Morgan, Piper Sandler, Jefferies, and William Blair are acting as joint book-running managers for the offering, with Stifel, Wells Fargo Securities, and BTIG also participating as book-running managers [1].
BillionToOne Announces Launch of Initial Public Offering Roadshow